文献速递医学人工智能与信息学新药、器械与细胞基因治疗研发医学教育与科研方法

FDA对医疗保健与生物医学中人工智能监管的视角

FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine.
PubMed 文献 · JAMA · 2025-01-01

该特别通讯回顾了美国食品药品监督管理局(FDA)对人工智能(AI)的监管历史,指出FDA已授权近1000款AI赋能的医疗器械,并收到数百份在药物研发中使用AI的监管申请。文章提出监管需跨行业、跨政府及国际协调,采用全生命周期管理并纳入上市后性能监测,同时强调评估应聚焦患者健康结局。

要点

  • FDA已授权近1000款AI赋能的医疗器械,并收到数百份药物研发中使用AI的监管申请。
  • 健康AI监管需在所有受监管行业、美国政府及国际组织间协调。
  • 全生命周期管理方法应纳入反复的本地上市后性能监测,作为健康AI开发的核心。

核心结论

  • FDA的强有力监管通过聚焦评估来促进受监管技术的发展以改善健康,从而保护行业的长期成功。
  • FDA将继续在确保安全、有效和可信赖的AI工具方面发挥核心作用,以改善患者和临床医生的生活。
  • 所有相关实体都需要以这项变革性技术应有的严谨态度来关注AI。

研究设计与样本

  • 该文为特别通讯,回顾了FDA对AI的监管历史,并提出了AI在医疗产品开发、临床研究和临床护理中的潜在用途及监管系统适应AI独特挑战时值得考虑的概念。

主要发现

  • FDA已授权近1000款AI赋能的医疗器械。
  • FDA已收到数百份在药物发现和开发中使用AI的监管申请。
  • 健康AI监管需要在所有受监管行业、美国政府以及国际组织之间进行协调。
  • 监管机构需要推进灵活的机制,以跟上AI在生物医学和医疗保健领域的变化步伐。
  • 申办者需要透明地说明AI在上市前开发中的使用,监管机构需要具备评估此类使用的专业能力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Advances in artificial intelligence (AI) must be matched by efforts to better understand and evaluate how AI performs across health care and biomedicine as well as develop appropriate regulatory frameworks. This Special Communication reviews the history of the US Food and Drug Administration's (FDA) regulation of AI; presents potential uses of AI in medical product development, clinical research, and clinical care; and presents concepts that merit consideration as the regulatory system adapts to AI's unique challenges. OBSERVATIONS: The FDA has authorized almost 1000 AI-enabled medical devices and has received hundreds of regulatory submissions for drugs that used AI in their discovery and development. Health AI regulation needs to be coordinated across all regulated industries, the US government, and with international organizations. Regulators will need to advance flexible mechanisms to keep up with the pace of change in AI across biomedicine and health care. Sponsors need to be transparent about and regulators need proficiency in evaluating the use of AI in premarket development. A life cycle management approach incorporating recurrent local postmarket performance monitoring should be central to health AI development. Special mechanisms to evaluate large language models and their uses are needed. Approaches are necessary to balance the needs of the entire spectrum of health ecosystem interests, from large firms to start-ups. The evaluation and regulatory system will need to focus on patient health outcomes to balance the use of AI for financial optimization for developers, payers, and health systems. CONCLUSIONS AND RELEVANCE: Strong oversight by the FDA protects the long-term success of industries by focusing on evaluation to advance regulated technologies that improve health. The FDA will continue to play a central role in ensuring safe, effective, and trustworthy AI tools to improve the lives of patients and clinicians alike. However, all involved entities will need to attend to AI with the rigor this transformative technology merits.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Warraich HJ, Tazbaz T, Califf RM, et al. FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine. JAMA. 2025. PMID: 39405330. doi:10.1001/jama.2024.21451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。